Cytokinetics, Incorporated (CYTK)
NEUTRALFundamental
32
Preço
$77.59
Capitalização de Mercado
$10.70B
Parte 1 · Quanto vale a empresa
Visão Geral
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$68M
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$-894M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$-535M
Capital Próprio Total
$-660M
Passivo Total
$2.08B
Rácio de Liquidez
6.66
Cobertura de Juros
13.43
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$65.59
Preço Atual
$77.59
Margem de Segurança
-18.3%
Intervalo de Valor Justo
$42.64 - $88.55
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
119.0%
Rácio P/B
-
P/FCF
-
Margem Bruta
-
ROIC
-32.1%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
-32.1%
WACC
8.0%
ROIC − WACC
-40.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (6)
- Price CAGR 20.26%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 9.6%
- Analyst Consensus 89% Buy
Reprovado (11)
- EPS shows upward trend
- ROIC -32.1%
- Operating Margin -1046.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -131.2%
- Earnings Surprise avg -12.0%
- Share Dilution 7.1%
- Net Margin Trend -1321.1% vs -707.2%
- Piotroski F-Score 2/9
Indisponível (10)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A emitir novas ações, diluindo a participação
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Robert I. Blum | CEO, President & Director | 61 |
| Mr. Sung H. Lee | EVP & CFO | 55 |
| Mr. Jeffrey J. Hessekiel J.D. | Executive VP, Chief Legal & Administrative Officer | 56 |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research & Development | 61 |
| Mr. Andrew M. Callos | Executive VP & Chief Commercial Officer | 56 |
| Dr. James H. Sabry M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 67 |
| Dr. James A. Spudich Ph.D. | Co-Founder & Member of Scientific Advisory Board | 83 |
| Mr. Jeff Lotz | Vice President of Sales & Operations | - |
| Ms. Holly Laughlin | VP of Accounting & Corporate Controller | - |
| Mr. Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations & Technical Operations | 66 |
Risco de Auditoria
5
Risco do Conselho
3
Risco de Remuneração
8
Risco dos Direitos dos Acionistas
7
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for CYTK, sourced from Markets Gazette.
- 3/9/2026POSITIVECytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
A significant insider transaction at Cytokinetics Inc. has been reported, with an executive exercising stock options valued at over $920,000. This occurs as the company's cardiac drug candidate progresses towards market entry. The exercise of options by an insider often signals confidence in the company's future prospects and the value of its stock. Coupled with the impending market launch of a key therapeutic, this event suggests positive momentum for Cytokinetics, potentially attracting further investor interest and supporting share price appreciation.
- 2/24/2026NEUTRALCytokinetics (CYTK) Q4 2025 Earnings Transcript
The financial community is keenly awaiting the Q4 2025 earnings transcript from Cytokinetics (CYTK). While specific details are not yet available, the analysis of such documents is crucial for investors looking to assess the biopharmaceutical company's operational performance and future prospects. Transcripts offer direct insights into management discussions regarding financial results, drug pipeline advancements, and growth strategies. Analysts will closely monitor any indications concerning key drugs like omecamtiv mecarbil or aficamten, as well as projections for the current fiscal year. The current lack of specific data suggests a cautious approach, but the release is a standard event providing transparency and a basis for informed decisions.
via Markets Gazette